Last reviewed · How we verify

NCT06915961

Epididymis Protein 4 and Pulmonary Function With Quality Improvement Protocol Among Cystic Fibrosis Patients

Recruiting now Last updated 8 April 2025
What this trial tests

trial in Cystic Fibrosis (CF) in 35 participants. Currently enrolling.

Timeline
7 October 2024
Primary endpoint
7 October 2025
12 December 2025

Quick facts

Lead sponsorAin Shams University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment35
Start date7 October 2024
Primary completion7 October 2025
Estimated completion12 December 2025
Sites1 location across Egypt

Conditions studied

Sponsor

Ain Shams University

Who can join

6 and older, any sex, with Cystic Fibrosis (CF). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To implement a quality improvement plan aimed at achieving a 5% increase in the Forced expiratory volume in 1st second (FEV1) (% predicted value) in cystic fibrosis (CF) patients with impaired pulmonary function parameters over 12 months. Additionally, the plan aims to measure serum human epididymis protein 4 (HE4) levels in the studied subjects before and after pulmonary function improvement.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cystic Fibrosis (CF)

Currently open trials in the same condition.

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915961.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing